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Strongyloides stercoralis is a parasite that causes strongyloidiasis, a neglected tropical dis-
ease. S. stercoralis is a soil-transmitted helminth that is widely distributed in tropical and
subtropical regions of the world. Strongyloidiasis can occur without any symptoms or as a
chronic infection characterized by mild, unspecific symptoms such as pruritus, abdominal
pain or discomfort; respiratory impairment also may manifest as a potentially fatal hyperin-
fection or disseminated infection. Most studies on strongyloidiasis in Spain have been
related to chronic forms in immigrants or travellers from endemic zones and have mainly
analysed out-patient populations. Studies of the impact of strongyloidiasis cases admitted to
hospitals in Spain are lacking. Therefore, the aim of this study was to analyse the impact of
strongyloidiasis in hospital care in Spain.
Methodology
We designed a retrospective descriptive study using the Minimum Basic Data Set (MBDS,
CMBD in Spanish) for inpatients with ICD-9: 127.2 (strongyloidiasis) diagnoses admitted to
hospitals in the Spanish National Health System between 1998 and 2014.
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Principal findings
A total of 507 hospitalizations with diagnosis of strongyloidiasis were recorded, 324 cases
(63.9%) were males. The mean (±SD) age was 42.1±20.1 years. The impact of strongyloidi-
asis on the total population of Spain was 0.06 cases per 105 person-years, and the infection
burden increased progressively over time (from 0.01 cases per 105 person-years in 1999 to
0.10 cases per 105 person-years in 2014). 40 cases (7.9%) died. The total cost was approxi-
mately €8,681,062.3, and the mean cost per patient was €17,122.4±97,968.8.
Conclusions
Our data suggest that strongyloidiasis is frequent in Spain and is increasing in incidence.
Therefore, it would be desirable to improve the oversight and surveillance of this condition.
Due to the fact that strongyloidiasis can be fatal, we believe that there is a need to establish
risk categories for inclusion in national guidelines/protocols for screening individuals at risk
of developing strongyloidiasis.
Introduction
Strongyloidiasis is mainly caused by Strongyloides stercoralis. Its transmission occurs in areas
where poor hygienic conditions and humid, warm climate permit the free-living cycle of the
parasite. Strongyloidiasis is usually acquired by walking barefoot on infested soil and is an
endemic infection in the tropics and subtropics. The existing information suggests that S. ster-
coralis infections affect between 10% and 40% of the population in many tropical and subtropi-
cal countries. The global prevalence of S. stercoralis has increased within recent years due to
infections in many endemic areas, specially Eastern, Southern and central Europe, Caribbean
Islands, Southeast Asia, Latin America and sub-Saharan Africa[1,2]. The continued increase in
the infection rate is solely attributed to poor personal hygiene, insufficient drinking water sup-
ply, unsatisfactory sanitary measures, and a lack of knowledge about the disease in high-risk
populations[1]. In Europe, mainly in the Mediterranean area[3,4] including Spain, autochtho-
nous cases have been reported[5,6], although most of the described cases are imported[7].
Strongyloidiasis can be suspected in symptomatic patients with digestive, respiratory or cuta-
neous complaints; however, asymptomatic eosinophilia and even ‘silent’ infections constitute
the vast majority of infections in endemic areas[7]. Strongyloidiasis is one of the most difficult
parasitic diseases to diagnose because suffer the lack of a diagnostic gold standard and relies
on traditional diagnostic methods based on the visualization of S. stercoralis in stools (direct
stool examination vs formalin-ethyl acetate concentration vsHarada mori, vs Baermann con-
centration vs agar plate culture) with different performance. Moreover, serologic tests have
also different performance, recent tests developped with recombinant antigen demonstrate
very good sensitivity and specificity. Also stool PCR is a promising diagnostic method. In addi-
tion, the sensitivity and specificity of this method vary among different patient groups[8]. In
humans the larvae can also penetrate the skin or the intestinal mucosa to establish a cycle of
repeated endogenous reinfection, this endogenous autoinfection cycle can possibly persist for
a lifetime[9].The distinction between disseminated infection and hyperinfection is not strictly
defined, but the hyperinfection syndrome implies the presence of signs and symptoms attrib-
utable to increased larval migration, with a increase larval burden but without the spread of
the larvae outside the usual migration pathway, and disseminated disease implies larval
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migration to other organs. Development or exacerbation of gastrointestinal and pulmonary
symptoms has been observed, and the detection of increased numbers of larvae in stool and
sputum is the hallmark of hyperinfection. Hyperinfection syndrome has been described as late
as 64 years after an individual has left an endemic area[9,10]. Both the hyperinfection and dis-
seminated forms can result with fulminant and frequently fatal clinical presentations in immu-
nosuppressed patients (hematological malignancies, transplant recipients, human T-cell
lymphotropic virus type 1 (HTLV-1) infected patients, and those on corticosteroid treatment)
[1,11].
In general, data on the impact of strongyloidiasis cases admitted to hospital are scarce[12–
14]. The aim of this study was to analyse the impact of hospital cases of strongyloidiasis in
Spain and to determine the evolution of strongyloidiasis incidence between 1998 and 2014.
Materials and methods
The design was a retrospective descriptive study for inpatients classified under the diagnosis
code ICD-9: 127.2 (strongyloidiasis) admitted to hospitals within the Spanish National Health
System between 1998 and 2014. The National Health System (NHS) provides free medical care
to 99.5% of the Spanish population, although those persons not covered by the NHS can
receive care at public hospitals. Since 2005, the NHS surveillance and epidemiology depart-
ment has provided patient data through the Conjunto Minimo Basico de Datos (CMBD as in
Spanish), which is a national version of the European Minimum Basic Data Set (MBDS) that
receives some information from private hospitals. It’s the largest administrative database of
inpatient and main source of information on morbidity, according to the demographic charac-
teristics of the patients. MBDS containing valuable information on multiple aspects of hospital
activity, as diagnoses, type of patients that cause longer stays and suppose a higher hospital
cost, type of income (emergent or programmed), surgical procedures, type of financing and
distribution of resources, quality and variability of care practice. In addition, it allows us to
analyse the existing combinations between main diagnosis (pathological process that is consid-
ered the main cause or reason for the patient's admission to the hospital, according to optional cri-
teria), it’s codified by the "International Statistical Classification of Diseases—9 revision—
clinical modification" (ICD-9-MC), and secondary diagnoses, coexist with it at the time of
admission, or develop throughout the hospital stay, and influence the duration of treatment or
treatment), also they encoded by the ICD-9-MC. (Ministry of Health, Social Policy and Equal-
ity, http://www.mspsi.es/estadEstudios/estadisticas/cmbd/informes/notasMetodologicas.htm.)
This study analysed the data provided by one of existing surveillance systems in Spain, the
MBDS. Therefore, we work with existing primary data records, we don’t generate the data.
The MBDS includes data from all hospital discharges produced in the general hospital network
of the NHS. The data contained in these records are those established in the above-mentioned
MBDS and provide information on the characteristics of the patients treated (age and sex) and
the appropriate variables as related to the hospitalization episode. Also, it collects the variable
“average cost”, corresponds to the estimated average cost for each GRD in the process of esti-
mating weights and costs of the NHS of the version in force, calculated or updated for the ref-
erence year. The MBDS is a universal and mandatory registry. Thus, the MBDS provides us
information about 532 patients who have been admitted to the hospital during the years 1998–
2014, and we collected information regarding hospital admissions with the strongyloidiasis
code (ICD-9: 127.2) in diagnostic discharge reports. When patients were admitted with the
same diagnosis several times, we registered only the first admission for analysis. Twenty-five
patient records with missing data, such as age, gender or the city/region of residence, and
patients with diagnosis mixed intestinal helminthiasis (ICD-9: 127.8) were excluded from the
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study. Finally, we included in this study 507 hospitalized patients in the Spanish National
Health System between 1998 and 2014 with diagnoses of strongyloidiasis (ICD-9: 127.2). To
improve the analysis, the patients were stratified according to gender and age (0–9, 10–19, 20–
29, 30–39, 40–49, 50–59, 60–69, 70–79, 80–89, and 90–99 years). The data were analysed
anonymously.
Statistical analysis
The incidence rates were calculated by dividing the number of new cases of disease (numera-
tor) per year/period by the population at risk (denominator) during a period of time (person-
years) multiplied by 100,000 and expressed as “cases per 105 person-years”. As it is not possible
to accurately measure the disease-free periods, the total figure of the person-time at risk can be
satisfactorily estimated when the size of the population is stable by multiplying the average
population size studied by the duration of the observation period. Thus, the population at risk
was obtained from annual data published by the National Institute of Statistics (INE, http://
www.ine.es/) and the General Secretary of Immigration and Migration (Ministry of Employ-
ment and Social Security, http://extranjeros.empleo.gob.es/es/Estadisticas/index.html).
The incidence rates were computed by region and year in order to assess temporal and geo-
graphical patterns. The results in terms of mean rates by autonomous community were plotted
in maps for the whole study period. The trends in hospitalization rates were analysed by linear
regression for the whole study population and by age groups.
The results were expressed as a percentage for categorical variables and as the mean and
standard deviation (SD) or median, 25th and 75th percentiles for continuous variables. A chi-
squared test was used to compare the association between categorical variables, such as clinical
and demographics variables, and the measured outcome was expressed as the odds ratio (OR)
together with the 95% CI for OR. Continuous variables were compared with Student’s t-test or
the Mann-Whitney test for two groups, depending on their normal or non-normal distribu-
tions. Additionally, we applied the corresponding Logistic Regression Model for multivariate
analysis (dependent variable: qualitative or categorical), which allows us, from the regression
coefficients (β) of the independent variables introduced in the model, to directly obtain the OR
of each one of them. The construction of the logistic model was carried out by a "forward" type
automatic procedure, based on the likelihood ratio test. The goodness check of the fit of the
final model was based on the guidelines of Hosmer and Lemeshow. Thus, what is intended is
to express the probability of occurrence of the event as a function of variables that are pre-
sumed relevant or influential. We considered a statistically significant difference from chance
at a p-value <0.05. Data analysis was performed using SPSS 23 (Statistical Package for the
Social Sciences).
Ethics statement
This study involves the use of patient medical data from The MBDS. These data are hosted by
the Ministry of Health Social Services and Equality (MSSSI). Researchers working in public
and private institutions can request the databases by filling a questionnaire available on the
MSSSI website. In this questionnaire, a signed Confidentiality Commitment is required. All of
the data are anonymized and identified by the MSSSI before they are provided to applicants.
According to this Confidentiality Commitment signed with the MSSSI, researchers cannot
provide the data to other researchers; other investigators must request the data directly from
the MSSSI[15].
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The study protocol was approved by the Ethical Review Board of the Vall d’Hebron Univer-
sity Hospital (Barcelona, Spain). The procedures described here were performed in accordance
with the ethical standards described in the Declaration of Helsinki as revised in 2013.
Results
According to the inclusion criteria, 507 patients were hospitalized in the Spanish National
Health System between 1998 and 2014 with diagnoses of strongyloidiasis (ICD-9: 127.2). Fig 1
shows the annual distribution of cases during the study period and the annual incidence rates.
It shows that the number of cases increased over time (from 9 (1.8%) cases in 1998 to 49
(9.7%) cases in 2014) as did the incidence rate (from 0.01 cases per 105 person-years in 1999 to
0.10 cases per 105 person-years in 2014). The incidence rate of strongyloidiasis cases admitted
to the hospital relative to the total population of Spain was 0.06 cases per 105 person-years. No
data regarding the nationalities of the admitted patients were available, However, if we assume
that most patients with disseminated strongyloidiasis are foreign-born, and attribute all cases
observed in our data to this population, then the period incidence rate among foreign-born
people in Spain would be 0.85 cases per 105 person-years and the annual incidence rates for
foreigners show in Fig 1. Fig 2 shows the distribution of the cohort according to the regions in
which each hospital belongs.
We estimated the period incidence rates in each of the regions to assess the incidence rates
of strongyloidiasis cases admitted to the hospital located within each area. The highest rates
Fig 1. Temporal distribution of cohort during the study period: Cases and anual incidence rate (cases per 105 person-years). Data of
Minimum Basic Data Set 1998–2014.
https://doi.org/10.1371/journal.pone.0189449.g001
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were observed in La Rioja (0.18 cases per 105 person-years), Madrid (0.16 cases per 105 per-
son-years) and Murcia (0.15 cases per 105 person-years).
Regarding gender, 324 cases (63.9%) were males and 183 cases (36.1%) were females. The
male/female ratio was 1.8. The mean (±SD) age was 42.1±20.1 years (range 0–96), the median
(25th, 75th percentiles) value was 38 (29, 56) years. The highest number of cases was observed
in the 30- to 39-year-old age group (124 cases; 24.5%) as shown in Fig 3.
The main data for patients included in the study are summarized in Table 1.
In 407 cases (80.3%), hospital admission was an emergency, and in 96 cases (18.9%), the
hospitalization was pre-planned. In relation to the services that provided inpatient hospital
care, 198 cases (39.1%) were treated by Internal Medicine, 35 cases (6.9%) by Infectious Dis-
eases, 20 cases (3.9%) by Digestive Diseases, 17 cases (3.4%) by Paediatrics, 16 cases (3.2%) by
Haematology and 15 cases each (3.0%) by Intensive, Nephrology and Pneumology. The mean
hospital stay (SD) was 19.0±26.0 days (range 1–390 days), the median (25th, 75th percentiles)
value was 13 (7, 23) days.
Fig 2. Number of cases and distribution of the cohort according to the autonomous community to which the hospital belongs 0–5%.
https://doi.org/10.1371/journal.pone.0189449.g002
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In 149 cases (29.4%), strongyloidiasis was the primary diagnosis/main diagnosis that caused
hospitalization, in 115 (22.7%) cases, strongyloidiasis was a secondary diagnosis in 80 (15.8)
strongyloidiasis was a third diagnosis, and in 163 (32.2%) cases was fourth diagnosis or
superior.
Most patients (494, 97.4%) had comorbidity. We have collected information about the
other diagnoses/comorbidities would have been relevant, as Infectious and parasitic diseases
(ICD-9, codes 001–139) orMalignant neoplasm of lymphatic and hematopoietic tissue (ICD-9,
codes 200–208) and we present in Table 2.
In these patients, infectious comorbidity was more frequent. Highlight, 102 patients
(20.1%) co-infected with HIV (ICD-9, code 042), 92 patients (18.1%) co-infected with other
Helminthiases (ICD-9, codes 120–129, except code 127.2 Strongyloidiasis), and in the group of
Rickettsioses and other arthropod-borne diseases (ICD-9, codes 080–088), there were 23 cases
(4.5%) co-infected withMalaria (ICD-9, code 084.0). After reviewing 507 cases, only one case
(0.2%) was co-infected with HTLV-I (ICD-9, code 079.51), and none HTLV-II (ICD-9, code
079.52), and 2 cases (0.4%) meningeal tuberculosis (ICD-9, code 013), without specifying
more information.
On the other hand,Malignant neoplasm of lymphatic and hematopoietic tissue presented 29
cases (5.7%) in total. Of them, 6 cases (1.2%) were Other malignant lymphomas, unspecified
Fig 3. Distribution of the cohort by age groups.
https://doi.org/10.1371/journal.pone.0189449.g003
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site, extranodal and solid organ sites (ICD-9, 202.80) and 1 case (0.2%) was Other malignant
lymphomas, intra-abdominal lymph nodes (ICD-9, 202.83).
We observed a crude mortality of 40 cases (7.9%). The mortality among those 149 patients
presenting strongyloidiasis as a first diagnosis was 4.7% (7 cases), meaning that a primary diag-
nosis of strongyloidiasis was associated with 17.5% of all deaths.
The risk of mortality in the cohort was three times higher (OR = 2.7; 95% CI, 1.3–5.5;
p = 0.004) when the diagnosis of strongyloidiasis was among the first 3rd in order, or later (28
vs. 12 dead). No significant differences between mortality and gender were observed
(p = 0.238), but there were statistically significant differences regarding age in which the risk
of death doubled after age 40 (OR = 1.9; 95% CI, 1.1–3.7; p = 0.050; 25 vs. 15 dead). The mean
(±SD) age (range) of the patients who died was 49.1±20.25 (7–83) years vs. 41.51±20.07 (0–96)
years in the rest of the cohort (p = 0.022). The highest mortality occurred in patients co-
infected with Human Immunodeficiency Virus (HIV), 14 dead; 35.0%, (OR = 2.3; 95% CI,
1.1–4.6; p = 0.014). Themultivariate logistic regression model confirmed that age is a risk
marker [Exp(B) = 2.0; 95%CI, 1.02–3.92; p = 0.042] that associated with late diagnosis (3rd or
more) [Exp(B) = 2.8; 95%CI, 1.39–5.69; p = 0.004], doubles and triples mortality risk in these
patients.
In relation to the hospital finances, 92.1% (467 cases) belonged to hospitals in the public
Social Security System (Table 1). The total cost was approximately €8.681.062, and the mean
cost per patient was €17.122.4±97.968.8 (2 cases cost €0 to 1 case had a maximum cost of
€1.543.880). The 149 patients who presented strongyloidiasis as first diagnosis represented a
Table 1. Main data in patients included in the study.
ICD-9: 127.2 = 507 cases, n (%)
Gender: male 324 (63.9)
Age (years), Mean ± SD (range) Median (25th, 75th percentiles) 42.1 ± 20.1 (0–96)
38 (29, 56)
Type of admission
From the emergency service 407 (80.3)




Transfer to another Hospital 9 (1.8)
Voluntary discharge 1 (0.2)




Social Security 467 (92.1)
Private 29 (5.7)
Mutual Healthcare 1 (0.2)
Work accidents 1 (0.2)
Traffic accidents 1 (0.2)
Mixed financing 1 (0.2)
Other/unknown 7 (1.4)
Hospital stay (days), Mean ± SD (range) Median (25th, 75th
percentiles)
19.0 ± 26.0 (0–390)
13 (7, 23)
https://doi.org/10.1371/journal.pone.0189449.t001
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total cost for our NHS of 832.521,34€, with a mean cost of 5.587,39€ (SD 21.436,41€, range
1.063,31–259.040€).
Discussion
We described a series of 507 cases of strongyloidiasis admitted to hospitals between 1998 and
2014; the incidence rate was 0.06 cases per 105 person-years. This rate increased ten-fold during
the study period. Most cases were male (63.9%), and the mean age was 42.1±20.1 years. The
mean hospital stay was 19.0±26.0 days. In 264 cases (52.1%), strongyloidiasis was ranked as the
primary or secondary diagnosis and thus was most likely the cause of admission. The total cost
of the series was approximately €8.681.062, with a mean cost of 5.587,39€ (SD 21.436,41€). The
crude mortality was 7.9%, but the mortality risk increased for those aged above 40, those pre-
senting strongyloidiasis among their first three diagnoses and those co-infected with HIV.
Strongyloidiasis is an emerging global infection, and one of the most neglected helminth
infections[1]. In contrast with other parasites, S. stercoralis has a very particular autoinfection
life-cycle entirely within the human host that leads to chronic infections remaining undetected
for decades. In addition, S. stercoralis is the only helminth that can lead to systemic infection
with high parasite densities and severe to potentially fatal complications, especially in immu-
nosuppressed hosts.
S. stercoralis is an endemic world-wide, heterogeneously distributed parasite with estimate
prevalence up to 100 million infected people[1]. Many epidemiological aspects such as the real
Table 2. Comorbidity associated with strongyloidiasis (127.2).
CODES DISEASES Freq. %
(001–139) INFECTIOUS AND PARASITIC DISEASES
001–009 Intestinal infectious diseases 53 10.4
010–018 Tuberculosis 45 8.9
020–027 Zoonotic bacterial diseases 2 0.4
030–041 Other bacterial diseases 126 24.8
042 Human immunodeficiency virus (HIV) infection 102 20.1
045–049 Poliomyelitis and other non-arthropod-borne viral diseases and prion diseases of central nervous system 20 3.9
050–059 Viral diseases accompanied by exanthem 13 2.5
060–066 Arthropod-borne viral diseases 1 0.2
070–079 Other diseases due to viruses and chlamydiae 52 10.2
080–088 Rickettsioses and other arthropod-borne diseases 43 8.5
090–099 Syphilis and other venereal diseases 18 3.5
110–118 Mycoses 53 10.4
120–129* Helminthiases* 92 18.1
130–136 Other infectious and parasitic diseases 19 3.7
137–139 Late effects of infectious and parasitic diseases 1 0.2
(200–208) MALIGNANT NEOPLASM OF LYMPHATIC AND HEMATOPOIETIC TISSUE
200 Lymphosarcoma and reticulosarcoma and other specified malignant tumors of lymphatic tissue 2 0.4
201 Hodgkin’s disease 2 0.4
202 Other malignant neoplasms of lymphoid and histiocytic tissue 7 1.4
203 Multiple myeloma and immunoproliferative neoplasms 5 1.0
204 Lymphoid leukemia 11 2.2
205 Myeloid leukemia 2 0.4
*Except 127.2 Strongyloidiasis
https://doi.org/10.1371/journal.pone.0189449.t002
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burden of the mortality and morbidity of S. stercoralis infection are poorly understood[16],
and information on infection rates/prevalence of the parasite is scarce[17].
Therefore, current rates of infection remain underestimated in many countries due to the
following reasons[2]: i) the optimal diagnostic strategy, both for epidemiological surveys and
for individual diagnosis and screening, has yet to be defined and certainly deserves further
research[18], ii) inadequate diagnostic methods with a low sensitivities are used (stool micros-
copy such as formalin-ether concentration), and therefore, better tools are needed for a more
correct estimation of S. stercoralis prevalence, using at least one of the best available diagnostic
methods in stools such as Baermann or Koga agar plate culture and adding an accurate sero-
logic test when possible, iii) low parasitic load[2], iv) uncertain clinical symptoms[1,19,20] and
v) a low index of suspicion among health care providers, especially in non-endemic countries
[11,21]
Few European studies have provided data on the prevalence, diagnosis and treatment of
infections with S. stercoralis. Most reports have been focused on immigrants and refugees from
endemic countries, either through population or hospital-based studies, and considering all of
the data available, this infection is clearly underestimated[19]. Only a small number of cases
have considered whether infections were autochthonous or imported by travellers. Immigrants
accounted for up to 90% of the diagnoses and, therefore, surveillance systems and diagnostic
programmes should be focused on that population[7,21]. Thus, in the series reported by
Ramirez Olivenza et al., there were no autochthonous or disseminated cases[7]. In our study
due to the methodological limitations, it was not possible to assess the nationality of the
patients, although given the current situation of strongyloidiasis infection in Spain, most of the
cases were immigrants or travellers[17].
Despite the high impact of strongyloidiasis cases admitted to hospital, we found no epide-
miological studies describing the effect of these cases. The most severe cases have been
reported in western countries or in other affluent countries where the prevalence of the infec-
tion is low, and about half the cases are seen in migrants[22]. In most African, Asian, and
Latin American countries, reports of severe and fatal strongyloidiasis are lacking or exceed-
ingly rare, meaning that most cases may be missed[16]. Many isolated case reports on the
emergence of the disease in different parts of the world that are non-endemic for this infection
are being published. Most of these case studies refer to disseminated cases or cases with hyper-
infection syndrome and belong to patients with immunosuppressive diseases, such as those
receiving corticosteroid therapy, organ transplant recipients, and patients with haematological
malignancies or other debilitating diseases[1]. In our work, we showed that during the study
period, the incidence rate of strongyloidiasis cases admitted to hospitals in Spain was 0.06
cases per 105 person-years, a significant figure considering that most cases can be silent or
present with scarce symptoms, which is likely to lead to an underestimation of total real preva-
lence. Therefore, the real impact may be greater, and the current numbers may be the tip of
the iceberg for strongyloidiasis in Spain. The increase in incidence rate of Strongyloidiasis
over time may be due to several reasons: an increase awareness among physicians overtime
and better diagnostic procedure; an increase number of travellers to endemic countries and
immigration from them; finally, there are more immunocompromised patients.
Strongyloidiasis is typically asymptomatic in immunocompetent hosts, despite chronic
infection. In hosts with defects in cell-mediated immunity, such as solid organ transplant
recipients, strongyloidiasis can manifest as hyperinfection syndrome and/or disseminated dis-
ease with a risk of sepsis that reaches 50% secondary to a bacteraemia, pneumonia, meningitis,
or peritonitis usually caused by an enterophatogens or polymicrobial agent gaining access to
sites beyond the intestinal tract via disrupted mucosa or by larval migration itself[11]. The
mortality rate of hyperinfection/disseminated strongyloidiasis is exceptionally high and ranges
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from 50 to 80%[1]. Early and active treatment may improve patient outcomes, but the mortal-
ity rate still ranges up to 30–71%[23]. If untreated, the mortality rate of disseminated disease
approaches 100%[24]. In our work, however, the global mortality reached 7.9%.
Thus, in our work, only 30% of patients had strongyloidiasis as the primary diagnosis, so a
better diffusion of the available information is badly needed, and collaboration among differ-
ent specialists is desirable in order to provide common and adequate guidelines and protocols
for screening for strongyloidiasis before the initiation of immunosuppressive therapy should
be considered[23]. In addition, treatment of the chronic infection is mandatory to prevent life-
threatening infection in at risk patients[1,22].
Despite these figures, strongyloidiasis is not rare and not always perceived as a relevant
health problem not only by the general population but also by the medical community[19].
Otherwise, encoding errors may exist and cannot be amended as the data included in the
MBDS are irreversible. The MBDS does not provide information about parasite diagnoses of
strongyloidiasis, and this impairs the quality of data.
The main limitation of our work was the initial selection and detection bias. Despite their
limitations, administrative databases (such as MBDS) have proven to be a valuable source of
information. MBDS validity depends on the quality and completeness with which the hospital
discharge report has been completed. Even if the MBDS provided information from a network
of hospitals that covers more than 99% of the population living in Spain, it only considers the
cases admitted to public hospital care; cases in private clinics and outpatients (mainly immi-
grants) were not included in this study. MBDS are data collected at hospital discharge. It is
impossible to analyze causality or temporal sequence. Therefore, it is very difficult to analyze
the complications. Therefore, we can assume that the actual incidence of strongyloidiasis is
even higher than the incidence estimated in this study. As some authors indicate, the incidence
rate is curiously low in areas where irregular sub-Saharan immigration is greater[25]. The
ICM-9 only describes strongyloidiasis as a whole entity and does not consider the different
clinical spectrum of the disease, and it is therefore impossible to determine how many cases
were really sick with strongyloidiasis and how many presented with S. stercoralis infection at a
point during hospital admission without it being a cause of disease. Unfortunately, no nation-
ality data were available, and thus, we cannot confirm whether these cases were likely to be
autochthonous or imported. As an advantage, ours is the first multicentre report on the sur-
veillance of strongyloidiasis cases admitted to hospitals in Spain (1998–2014). In addition, the
MBDS has been proven to be a trusted source for many epidemiological studies as it provides
reliable information to support decision-making based on the ICD-9 codification carried out
by medical doctors without being subject to the lack of diagnostic tools in outpatient care,
leading to under-diagnosis or reporting deficiencies. It remains dependent only on the popula-
tion’s health seeking behaviours or healthcare accessibility.
In summary, our data suggests that strongyloidiasis in Spain is frequent and is increasing in
incidence. Therefore, it would be desirable to improve the oversight and surveillance of this
disease. Because strongyloidiasis can be fatal in immunocompromised individuals, we believe
that risk categories must be established for inclusion in national guidelines/protocols for
screening individuals as candidates for immune-suppressant therapies and immigrants with
eosinophilia.
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